• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Deciphera Pharmaceuticals Inc. (Amendment)

    2/9/24 4:30:32 PM ET
    $DCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DCPH alert in real time by email
    SC 13G/A 1 formsc13ga.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

    Deciphera Pharmaceuticals, Inc.

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    24344T101

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event which Requires filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)
    ☐ Rule 13d-1(c)
    ☒ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
     

     

    CUSIP No. 24344T101 Schedule 13G Page 2 of 5 Pages

     

    1

    Names of Reporting Persons

     

    Brightstar Associates LLC

     
    2 Check the Appropriate Box if a Member of a Group

    (a) [  ]

    (b) [  ]

     

    3

    SEC Use Only

     

     
    4

    Citizen or Place of Organization

     

    Missouri

     

    Number of Shares Beneficially Owned by Each Reporting Person With

     

    5

    Sole Voting Power

     

    23,059,708

    6

    Shared Voting Power

     

    0

    7

    Sole Dispositive Power

     

    23,059,708

    8

    Shared Dispositive Power

     

    0

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    23,059,708

     
    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    [  ]
    11

    Percent of a Class Represented by Amount in Row 9

    28.2%

     
    12

    Type of Reporting Person

     

    Limited Liability Company

     

     

     
     

     

    CUSIP No. 24344T101 Schedule 13G Page 3 of 5 Pages

     

    ITEM 1. (a)Name of Issuer:

     

    Deciphera Pharmaceuticals, Inc. (the “Issuer”).

     

      (b) Address of Issuer’s Principal Executive Offices:

     

    200 Smith Street, Waltham, MA 02451

     

    ITEM 2. (a)Name of Person Filing:

     

    This statement is filed on behalf of Brightstar Associates LLC (the “Reporting Person”).

     

      (b)Address or Principal Business Office:

     

    The business address of the Reporting Person is 1020 Central Street, Suite 300, Kansas City, Missouri 64105.

     

      (c)Citizenship of each Reporting Person is:

     

    The Reporting Person is incorporated in the State of Missouri.

     

      (d)Title of Class of Securities:

     

    Common Stock, par value $0.01 per share (the “Common Stock”).

     

      (e)CUSIP Number:

     

    24344T101

     

    ITEM 3.

     

    Not applicable.

     

    ITEM 4.Ownership

     

    The ownership information presented below represents beneficial ownership of shares of Common Stock of the Issuer as of the date of this filing, based upon 80,800,062 shares of Common Stock outstanding as of January 31, 2024, as disclosed in the Issuer’s annual report on Form 10-K as filed with the Securities and Exchange Commission on February 6, 2024.

     

    (a) Amount beneficially owned:

     

    The Reporting Person is the record holder of 23,059,708 shares of Common Stock and a currently exercisable warrant for the purchase of up to an additional 48,136 shares of Common Stock. The warrant contains a limitation on exercise that provides that the warrant may not be exercised to the extent that it would cause the Reporting Person to beneficially own more than 28.22% of the then-outstanding Common Stock.

     

     
     

     

    CUSIP No. 24344T101 Schedule 13G Page 4 of 5 Pages

     

    The Reporting Person is managed by a three-person managing board consisting of Greg A. Hamilton, Mark K. Fallon, and Timothy Fritzel, and all action relating to the voting or disposition of these shares requires approval of a majority of the board. Such individuals expressly disclaim any beneficial ownership over the shares held by the Reporting Person.

     

    (b) Percent of class: 28.2%

     

    (c) Number of shares as to which the person has:

     

      (i)Sole power to vote or to direct the vote: 23,059,708
      (ii)Shared power to vote or direct the vote: 0
      (iii)Sole power to dispose or to direct the disposition of: 23,059,708
      (iv)Shared power to dispose or to direct the disposition of: 0

     

    ITEM 5.Ownership of Five Percent or Less of a Class

     

    Not applicable.

     

    ITEM 6.Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

    ITEM 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

     

    Not applicable.

     

    ITEM 8.Identification and Classification of Members of the Group

     

    Not applicable.

     

    ITEM 9.Notice of Dissolution of Group

     

    Not applicable.

     

    ITEM 10.Certification

     

    Not applicable.

     

     
     

     

    CUSIP No. 24344T101 Schedule 13G Page 5 of 5 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 9, 2024

     

      Brightstar Associates LLC
         
      By: /s/ Greg A. Hamilton
      Name: Greg A. Hamilton
      Title: Member of the Board of Managers

     

     

     

    Get the next $DCPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DCPH

    DatePrice TargetRatingAnalyst
    11/20/2023$14.00Neutral
    JP Morgan
    10/30/2023$23.00Neutral → Overweight
    Piper Sandler
    8/10/2023$14.00 → $20.00Hold → Buy
    Stifel
    1/4/2023$22.00Neutral → Buy
    Guggenheim
    8/29/2022$25.00Outperform
    Cowen
    8/5/2022$23.00Mkt Perform → Mkt Outperform
    JMP Securities
    2/28/2022$11.00 → $6.00Equal-Weight → Underweight
    Barclays
    12/1/2021$25.00 → $15.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $DCPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • JP Morgan resumed coverage on Deciphera Pharmaceuticals with a new price target

      JP Morgan resumed coverage of Deciphera Pharmaceuticals with a rating of Neutral and set a new price target of $14.00

      11/20/23 7:26:00 AM ET
      $DCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Deciphera Pharmaceuticals upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Deciphera Pharmaceuticals from Neutral to Overweight and set a new price target of $23.00

      10/30/23 11:51:39 AM ET
      $DCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Deciphera Pharmaceuticals upgraded by Stifel with a new price target

      Stifel upgraded Deciphera Pharmaceuticals from Hold to Buy and set a new price target of $20.00 from $14.00 previously

      8/10/23 6:19:16 AM ET
      $DCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DCPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP & Chief Medical Officer Sherman Matthew L was granted 34,157 shares and returned 72,029 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Deciphera Pharmaceuticals, Inc. (0001654151) (Issuer)

      6/11/24 9:02:09 PM ET
      $DCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Kelly Thomas Patrick was granted 34,157 shares and returned 72,029 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Deciphera Pharmaceuticals, Inc. (0001654151) (Issuer)

      6/11/24 8:56:07 PM ET
      $DCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, Chief Development Officer Pitman Jama was granted 20,163 shares and returned 53,951 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Deciphera Pharmaceuticals, Inc. (0001654151) (Issuer)

      6/11/24 8:51:39 PM ET
      $DCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DCPH
    Leadership Updates

    Live Leadership Updates

    See more

    $DCPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • The Week in Canadian Press Releases: 10 Stories You Need to See

      A roundup of the most newsworthy press releases from Cision Distribution this week TORONTO, Oct. 6, 2023 /CNW/ - With thousands of press releases published each week, it can be difficult to keep up with everything on Cision. To help journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed. The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that

      10/6/23 6:18:00 AM ET
      $DCPH
      $SLF
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Life Insurance
      Finance
    • Deciphera Pharmaceuticals Announces Retirement of Daniel L. Flynn, Ph.D., and Appointment of Dashyant Dhanak, Ph.D., as Executive Vice President and Chief Scientific Officer

      — Director Ron Squarer Appointed Chairperson of the Board; James A. Bristol, Ph.D., continues as Board Member — Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that the Company's Founder, Executive Vice President, and Chief Scientific Officer, Daniel L. Flynn, Ph.D., will retire effective September 5, 2023 and will transition to a role as Senior Advisor to the Company. Dashyant Dhanak, Ph.D., has been appointed Executive Vice President and Chief Scientific Officer effective September 5, 2023. Dr. Dhanak brings over 30 year

      8/3/23 4:15:00 PM ET
      $DCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Deciphera Pharmaceuticals, Inc. Appoints Kelley Dealhoy as Chief Business Officer

      Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the appointment of Kelley Dealhoy as Senior Vice President and Chief Business Officer. Ms. Dealhoy brings 20 years of life science leadership experience to the role, and her responsibilities will include developing and leading the Company's business development efforts as well as supporting corporate strategy initiatives. "We are thrilled to welcome Kelley to our executive team as Chief Business Officer. Kelley has extensive leadership experience in pharmaceutical and biotechnology companies with a proven track record of building value through business development and strategic partnerships," said Steve Hoerter, President and Ch

      6/16/22 7:00:00 AM ET
      $DCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Deciphera Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Deciphera Pharmaceuticals, Inc. (0001654151) (Subject)

      2/14/24 4:26:20 PM ET
      $DCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Deciphera Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Deciphera Pharmaceuticals, Inc. (0001654151) (Subject)

      2/14/24 4:06:14 PM ET
      $DCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Deciphera Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Deciphera Pharmaceuticals, Inc. (0001654151) (Subject)

      2/14/24 2:26:21 PM ET
      $DCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DCPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono)

      OSAKA, Japan and WALTHAM, Mass., June 11, 2024 /PRNewswire/ -- Ono Pharmaceutical, Co., Ltd. (Chairman and CEO: Gyo Sagara, "Ono") today announced that it has successfully completed the tender offer, previously announced on April 30, 2024 to acquire all outstanding shares of common stock of a US biopharmaceutical company, Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH, CEO: Steven L. Hoerter, ", Deciphera", ))) for US$25.60 per share (total amount of approximately US$2.4 billion) net to the seller in cash, without interest thereon and less any applicable withholding taxes, through its wholly owned subsidiary, Topaz Merger Sub, Inc. ("Merger Sub"), established in the State of Delaware, United S

      6/11/24 8:30:00 AM ET
      $DCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet

      – MOTION Phase 3 Data Demonstrate Robust Efficacy, Clinically Meaningful Improvements in Quality-of-Life Measures, and Well-Tolerated Safety Profile, Positioning Vimseltinib as Potential New TGCT Treatment – – Company Expects to Submit a New Drug Application (NDA) in the Second Quarter of 2024 and Marketing Authorisation Application (MAA) in the Third Quarter of 2024 – Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that results from the Company's MOTION pivotal Phase 3 study of vimseltinib in patients with TGCT are being

      6/3/24 7:00:00 AM ET
      $DCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ONO Enters into a Definitive Agreement to Acquire Deciphera Pharmaceuticals

      OSAKA, Japan, April 30, 2024 /PRNewswire/ -- ONO Pharmaceutical, Co., Ltd., (TSE: 4528, Representative Director, Chairman of the Board and Chief Executive Officer: Gyo Sagara, "ONO") and Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH, Chief Executive Officer: Steven L. Hoerter, ", Deciphera", ))) today announced that on April 29, 2024 (Japan time), ONO and Deciphera entered into a definitive merger agreement under which ONO will acquire all outstanding shares of Deciphera common stock for US $ 25.60 per share in cash through a tender offer followed by a merger of a wholly owned subsidiary of ONO with and into Deciphera with Deciphera surviving as a wholly owned subsidiary of ONO (the "Acquisit

      4/30/24 7:00:00 AM ET
      $DCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DCPH
    Financials

    Live finance-specific insights

    See more
    • Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono)

      OSAKA, Japan and WALTHAM, Mass., June 11, 2024 /PRNewswire/ -- Ono Pharmaceutical, Co., Ltd. (Chairman and CEO: Gyo Sagara, "Ono") today announced that it has successfully completed the tender offer, previously announced on April 30, 2024 to acquire all outstanding shares of common stock of a US biopharmaceutical company, Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH, CEO: Steven L. Hoerter, ", Deciphera", ))) for US$25.60 per share (total amount of approximately US$2.4 billion) net to the seller in cash, without interest thereon and less any applicable withholding taxes, through its wholly owned subsidiary, Topaz Merger Sub, Inc. ("Merger Sub"), established in the State of Delaware, United S

      6/11/24 8:30:00 AM ET
      $DCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ONO Enters into a Definitive Agreement to Acquire Deciphera Pharmaceuticals

      OSAKA, Japan, April 30, 2024 /PRNewswire/ -- ONO Pharmaceutical, Co., Ltd., (TSE: 4528, Representative Director, Chairman of the Board and Chief Executive Officer: Gyo Sagara, "ONO") and Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH, Chief Executive Officer: Steven L. Hoerter, ", Deciphera", ))) today announced that on April 29, 2024 (Japan time), ONO and Deciphera entered into a definitive merger agreement under which ONO will acquire all outstanding shares of Deciphera common stock for US $ 25.60 per share in cash through a tender offer followed by a merger of a wholly owned subsidiary of ONO with and into Deciphera with Deciphera surviving as a wholly owned subsidiary of ONO (the "Acquisit

      4/30/24 7:00:00 AM ET
      $DCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results

      – Fourth Quarter 2023 Total Revenue of $48.3 Million and Full Year 2023 Revenue of $163.4 Million; QINLOCK® Net Product Revenue Increased 27% to $159.1 Million in 2023 Compared to 2022 – – Expects to Submit NDA for Vimseltinib in the Second Quarter of 2024 and MAA in the Third Quarter of 2024 in Tenosynovial Giant Cell Tumor (TGCT) – – Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study in 2L GIST Patients with Mutations in KIT Exon 11+17/18 Published in Nature Medicine; Final Overall Survival (OS) Results from INTRIGUE Study in 2L GIST Patients Presented at ASCO GI – – Cash Expected to Fund Operating and Capital Expenditures into the Second Half of 2026 – Deciphera

      2/6/24 7:00:00 AM ET
      $DCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DCPH
    SEC Filings

    See more
    • SEC Form 15-12G filed by Deciphera Pharmaceuticals Inc.

      15-12G - Deciphera Pharmaceuticals, Inc. (0001654151) (Filer)

      6/21/24 8:02:56 AM ET
      $DCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Deciphera Pharmaceuticals Inc.

      EFFECT - Deciphera Pharmaceuticals, Inc. (0001654151) (Filer)

      6/14/24 12:15:03 AM ET
      $DCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Deciphera Pharmaceuticals Inc.

      S-8 POS - Deciphera Pharmaceuticals, Inc. (0001654151) (Filer)

      6/11/24 5:18:25 PM ET
      $DCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care